Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Resources

About Retinal Disease:

Foundation Fighting Blindness
The mission of the Foundation Fighting Blindness, Inc. is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa (RP), macular degeneration, Usher syndrome, and the entire spectrum of retinal degenerative diseases.

AMD Alliance International
AMD Alliance International strives to bring knowledge, help and hope to individuals and families around the world affected by AMD.

Macular Degeneration Partnership
 The Macular Degeneration Partnership provides comprehensive, easily understood and up-to-the-minute information about macular degeneration for everyone who needs it, as well as supporting ongoing research in Macular Degeneration to help find new treatments and a cure for this sight-robbing disease.

Prevent Blindness America
Prevent Blindness America is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness America touches the lives of millions of people each year.

Macular Degeneration Research (American Health Assistance Foundation)
The American Health Assistance Foundation (AHAF) is an international nonprofit organization dedicated to finding cures for age-related degenerative diseases. The foundation funds research on Alzheimer's disease, macular degeneration, and glaucoma and provides the public with free information about risk factors, preventative lifestyles, and current treatments and coping strategies.

Hope for Vision
Hope For Vision provides the tools necessary for people to come together to share our common interest in this cause and to work together to raise funds for this critical research. HFV is comprised of thousands of dedicated volunteers and vision advocates in Communities of Hope across the country, who raise funds through special events and other activities. Guided by its Board of Visionary Scientists, HFV then distributes over 90 percent of funds raised directly to researchers at leading medical institutions nationwide.

National Alliance for Eye and Vision Research
The National Alliance for Eye and Vision Research (NAEVR) is a non-profit advocacy organization comprised of a coalition of 55 professional, consumer and industry organizations involved in eye and vision research. NAEVR's goal is to achieve the best eye and vision care for all Americans through advocacy and public education for eye and vision research sponsored by the National Institutes of Health (NIH), the National Eye Institute (NEI) and other federal research entities.

Lions Eye Institute
The Lions Eye Institute is leading the worldwide fight against blinding eye disease through our unique model — uniting the world's largest Eye Bank, our cutting-edge Ocular Research Center, and our Foundation together to create the leading institution for ocular science. We are advocates for the 45 million blind and visually impaired people across the globe, and our mission is to improve their vision and quality of life, and ultimately end blindness.

National Eye Institute (National Institutes of Health)
As part of the federal government's National Institutes of Health (NIH), the National Eye Institute's mission is to "conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and requirements of the blind."


About Clinical Trials:

US & International: www.clinicaltrials.gov
ClinicalTrials.gov is a registry and results database of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov provides information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals.

Avalanche Biotechnologies Prices Initial Public Offering of $102.0 Million of Common Stock

July 31, 2014

MENLO PARK, Calif., July 31, 2014 -- Avalanche Biotechnologies, Inc., a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts, commissions and estimated expenses. All of the shares of common stock are being offered by Avalanche. The Company's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading today under the ticker symbol "AAVL".

Read More

Read All Avalanche News